Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide Rechallenge in Recurrent Malignant Glioma by Using a Continuous Temozolomide Schedule The "Rescue" Approach. Cancer. 2008 Oct;113(8):2152-7.
Suh WW, Blackstock AW, Herman J, Konski AA, Mohiuddin M, Poggi MM, Regine WF, Cosman BC, Saltz L, Johnstone PA. ACR appropriateness criteria on resectable rectal cancer. International Journal of Radiation Oncology Biology Physics. 2008 Apr;70(5):1427-30.
Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: A retrospective review of the Fox Chase Cancer Center experience and a review of the literature. Clinical lung cancer. 2007 Mar;8(5):319-26.
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: A paradigm for the management of metastatic colorectal cancer. The oncologist. 2007 Jan;12(1):38-50.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mobuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1717-25.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Barsevick AM, Dudley WN, Beck SL. Cancer-related fatigue, depressive symptoms, and functional status. Nursing research. 2006 Sep;55(5):366-72.
Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN. Symptom cluster research: Conceptual, design, measurement, and analysis issues. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT. 2006 Jan;31(1):85-95.
Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY. 2006 Sep;102(3):432-9.
Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 2006 Nov;103(2):473-8.
Chang JY, Moughan J, Johnstone DW, Komaki R, Goldberg M, Langer CJ, Beadle BM, Owen J, Movsas B. Surgical patterns of care in operable lung carcinoma treated with radiation. JOURNAL OF THORACIC ONCOLOGY. 2006 Jul;1(6):526-31.
Henry LR, Goldberg M, Scott W, Konski A, Meropol NJ, Freedman G, Weiner LM, Watts P, Beard M, McLaughlin S, Cheng JD. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. ANNALS OF SURGICAL ONCOLOGY. 2006 Feb;13(2):214-20.
Langer CJ. Treatment of stage I-III non-small-cell lung cancer in the elderly - The Gridelli/Maione/Rossi article reviewed. ONCOLOGY-NEW YORK. 2006 Apr;20(4):385-+.
Masters GA, Li SG, Dowlati A, Madajewicz S, Langer C, Schiller J, Johnson D. A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group Study (E1501). JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):673-8.
Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: A radiation therapy oncology group (RTOG) analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(3):830-5.
Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. EPILEPSIA. 2006 Jul;47(7):1237-8.
Ozols RF, Bookman MA, Young RC, Du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. GYNECOLOGIC ONCOLOGY. 2006 Oct;103(1):1-6.
Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH, Eastern Cooperative Oncology Grp. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. JOURNAL OF THORACIC ONCOLOGY. 2006 Jun;1(5):441-6.
Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. Journal of Clinical Oncology. 2005 May;23(13):3008-15.
Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. Journal of Clinical Oncology. 2005 Jul;23(19):4330-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy radiotherapy therapy Oncology cancer surgery carboplatin trial survival randomized-trial ovarian cancer symptom clusters non-small cell lung cancer CARCINOMA cisplatin induction quality of life Obstetrics & Gynecology fatigue CHEMOTHERAPY paclitaxel PACLITAXEL RANDOMIZED-TRIAL management cyclophosphamide resection FLUOROURACIL radiation pain disease phase-iii Clinical Neurology BMI body weight CARBOPLATIN esophageal cancer sleep quality index PHASE-III initial treatment dose fractionation CHEMOTHERAPY REGIMENS comparing cisplatin DOCETAXEL TRIAL oncology dna-damage PHYSICAL-ACTIVITY PROSTATE-CANCER preoperative chemoradiation preclinical CISPLATIN single-agent GLIOBLASTOMA lung-cancer susceptibility group rtog PROGRESSION INFUSION tomography 5-fluorouracil topotecan inventory adenocarcinoma symptom management VINDESINE PLUS CISPLATIN transgenic mouse model model POOLED ANALYSIS outpatients pretreatment factors SURVIVAL ORAL VINORELBINE single-agent carboplatin smoking OBESITY MRI micro-imaging doublets fourth-line therapy second-line therapy toxicity early stage EOC stage-iii ovarian intergroup trial estrogen SAFETY PROFILE ORAL DOUBLETS randomized clinical-trial glioblastoma POSTMENOPAUSAL WOMEN OVERWEIGHT depressive symptoms PHASE-III TRIAL exisulind 1st-line treatment p-32 SYSTEMIC THERAPY SUPPORTIVE elderly cancer-patients biologic therapy lung cancer novel agent gender metaanalysis MGMT colorectal cancer symptoms General & Internal Medicine brain neoplasms functional status questionnaire PREOPERATIVE RADIOTHERAPY altered fractionation SINGLE-AGENT VINORELBINE doxorubicin Nursing TRANSGENIC MICE tumors RADIATION-THERAPY LEUCOVORIN MORTALITY leukemia group-b VITRO neoadjuvant depression population expression temozolomide gynecologic-oncology-group carcinoma ELDERLY-PATIENTS rectal cancer phase II trial refractory epilepsy seizure-temozolomide-oligodendroglioma-brain tumor intervention STAGE-III diagnosis BODY-MASS INDEX METRONOMIC CHEMOTHERAPY intraindividual changes appropriateness criteria Surgery neoadjuvant chemoradiotherapy socioeconomic-status CARE rechallenge sequential ADJUVANT THERAPY impact stage
Last updated on Thursday, June 04, 2020